LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ROSTAMZADEH Z.; SEPEHRVAND N.; YAHYAVI R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Seminar Paper

Paper Information

Seminar: BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY
Year:2007 | Issue:6

Download Full-Text

View:

110

Download:

Information Seminar Paper

Title

LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS

Author(s)

ROSTAMZADEH Z. | SEPEHRVAND N. | YAHYAVI R.

Keywords

Not Registered.

Abstract

Introduction: Hepatitis B virus infection has a higher mortality and is more likely to result in a carrier state in uraemic patients. Although the efficacy of hepatitis B vaccines in patients under chronic hemodialysis treatment has been well documented, the persistence of immunity in this population remains largely unknown.Method: In this study we have followed 141hemodialysis patients up to 3 years after primary hepatitis B vaccination to evaluate the persistence of immunity (as indicated by serum levels of antibody to hepatitis B surface antigen –anti-HBs- higher than or equal to 10 mIU/Mi.Results:85 (60.28%) patients developed anti-HBs levels above 10 mIU/mI after vaccination; the remaining 56(39.71%) vaccines were considered nonresponders and were given a booster dose that again failed to elicit an immunoresponse. After 3 years of follow-up, 21out of 56 (37.5%) responders had no detectable anti-HBs levels in the serum (antibody loss occurring during 1 year in 4cases within 1 and 2 years in 11, and within 2 and 3 years in 6 other cases.Conclusions: When compared with the responders that lost their antibodies during the follow-up period, those who remained immunoreactive 3 years after vaccination was initiated were younger and had higher anti-HBs levels at 8 months of follow-up. Two hepatitis B virus infections were detected among nonresponders during the follow-up period. Based on these data, we conclude that patients undergoing chronic hemodialysis therapy not only have lower response rates to hepatitis B vaccination than healthy adults, but also that these are frequently transient

Cites

No record.

References

No record.

Cite

APA: Copy

ROSTAMZADEH, Z., SEPEHRVAND, N., & YAHYAVI, R.. (2007). LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS. BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY. SID. https://sid.ir/paper/902578/en

Vancouver: Copy

ROSTAMZADEH Z., SEPEHRVAND N., YAHYAVI R.. LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS. 2007. Available from: https://sid.ir/paper/902578/en

IEEE: Copy

Z. ROSTAMZADEH, N. SEPEHRVAND, and R. YAHYAVI, “LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS,” presented at the BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY. 2007, [Online]. Available: https://sid.ir/paper/902578/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops